Menéndez R, Rodríguez-GonzálezMoro JM, Gros B, Echave M, Oyagüez I, Lwoff N, Egea-García M, Guijarro P
Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged ≥50 years in Spain: Preliminary results
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Álvarez-Sabín J, Masjuan J, Casado MA, Mar J, Oliva J, González-Rojas N
Costs in patients along first year poststroke in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Álvarez-Sabín J, Masjuan J, Yébenes M, Mar J, Oliva J, González-Rojas N
Disease burden of ischemic stroke along first year post-stroke in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
De Andres F, Vivancos J, Barriga FJ, Díaz F, Izquierdo L, Ortega MA, Castillo L, Ximénez-Carrillo A, Gómez-Escalonilla CI, Torres C, de Salas-Cansado M, Casado MA, Soto J, Gil-Nuñez A
Healthcare resource utilization and costs of cardioembolic stroke in the region of Madrid, Spain: preliminary results of CODICE study
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Sánchez-de la Rosa R, Sabater E, Casado MA
Cost analysis of glatiramer acetate versus fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Betegon L, Guilloteau I, Martin P, Woolmore A, Oyagüez I
The relative value of dasatinib versus imatinib as first-line treatment for chronic myeloid leukemiay
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Cobo M, De Castro J, Isla D, Lozano V, Oyagüez I, Castro-Gomez AJ
Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy
15th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012
Martinez-Raga J, Casado MA, González Saiz F, Oñate J
Budgetary impact analysis of Buprenorphine/Naloxone (Suboxone®) in opioid maintenance treatment in Spain
14th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Madrid, Spain 5-8 nov 2011
Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R